Ovarian function after autologous bone marrow transplantation.
OBJECTIVE
To determine the frequency of return of ovarian function after autologous bone marrow transplantation (ABMT), and the major factors that predict recovery.


METHODS
Records of 200 consecutive women who underwent ABMT at the University of Toronto Autologous Blood and Marrow Program (Toronto, Canada) were reviewed. Seventeen patients met the inclusion criteria, which were (1) alive at the time of evaluation, (2) disease-free at least 18 months after transplantation, (3) age younger than 50 years at transplantation, and (4) premenopausal before transplantation. Recovery of ovarian function was determined by pregnancy or regular menses, with no menopausal symptoms and an estradiol level greater than 20 pmol/L off hormonal therapy.


RESULTS
All 17 patients became menopausal immediately after ABMT. Five patients (29%) recovered ovarian function a median of 24 months post-ABMT (range, 6 to 48 months). The median age at transplantation of women with restored ovarian function was 19 years (range, 19 to 28 years) versus 30 years (range, 22 to 48 years) for those who did not regain function. Younger age at transplantation predicted ovarian recovery (P = .03) by means of a log-rank test. Only one of five women who regained ovarian function received total-body irradiation (TBI) compared with five of 12 women who did not. Univariate analysis suggested a trend for TBI to predict a sustained loss of ovarian function (P = .067). The number of regimens of induction or salvage chemotherapy that contained an alkylating agent ranged from none to five and was not predictive (P = .45).


CONCLUSIONS
All women became menopausal after ABMT but 29% recovered ovarian function. Younger age at transplantation predicted return of ovarian function, whereas TBI may have had a negative effect.
Schimmer
A D
AD
University of Toronto Autologous Blood and Marrow Transplant Program and the Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.
Quatermain
M
M
Imrie
K
K
Ali
V
V
McCrae
J
J
Stewart
A K
AK
Crump
M
M
Derzko
C
C
Keating
A
A
D000206:Actuarial Analysis; D000328:Adult; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008598:Menstruation; D008875:Middle Aged; D010050:Ovarian Function Tests; D010053:Ovary / Q000503:physiopathology*; D011247:Pregnancy; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D004958:Estradiol